Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Exenatide Once Weekly vs Insulin Detemir in Type 2 Diabetes (DURATION-3)
NCT01003184Phase 3Completed
- Sponsor
- AstraZeneca
- Start
- Oct 2009
- Primary completion
- Jul 2011
- Modality
- Peptides
- Countries
- 2
01
Overview
A Phase 3 trial of exenatide extended-release in type 2 diabetes mellitus (T2DM), sponsored by AstraZeneca. Started Oct 2009; status: completed.
02
Drugs
exenatide extended-release
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT01003184.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01003184.